Both are part of a new class of drugs known as GLP-1 receptor agonists, but they have some key differences in how they work and their overall efficacy
Get started with GLP-1 therapy
While glucagon is traditionally known for raising blood sugar, activating its receptor in a controlled way has been shown to increase energy expenditure and promote satiety, adding a powerful third dimension to the metabolic effects
Protecting Muscle Is Non-Negotiable Heres what too few clinicians are talking about: GLP-1s, by reducing appetite, can unintentionally reduce protein intake , putting your muscle mass at risk
GLP-1s require ongoing possibly lifelong injections to maintain results
has been on the advisory panel of, a consultant for, in the speaker's bureau of, owns shares in, and/or has received research support from 89bio, AstraZeneca, Boehringer Ingelheim, Cytoki Pharma, Eli Lilly, Gubra, Novo Nordisk, Merck Sharp & Dohme, Sanofi, Structure Therapeutics, Zealand Pharma, and Zucara
